Cymabay Therapeutics Inc (CBAY) concluded trading on Thursday at a closing price of $32.48, with 8.36 million shares of worth about $271.41 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 121.86% during that period and on March 21, 2024 the price saw a gain of about 0.03%. Currently the company’s common shares owned by public are about 113.86M shares, out of which, 110.65M shares are available for trading.
Stock saw a price change of 0.03% in past 5 days and over the past one month there was a price change of 0.90%. Year-to-date (YTD), CBAY shares are showing a performance of 37.51% which increased to 262.50% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.26 but also hit the highest price of $32.49 during that period. The average intraday trading volume for Cymabay Therapeutics Inc shares is 3.78 million. The stock is currently trading 0.45% above its 20-day simple moving average (SMA20), while that difference is up 14.25% for SMA50 and it goes to 77.47% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cymabay Therapeutics Inc (NASDAQ: CBAY) currently have 113.86M outstanding shares and institutions hold larger chunk of about 99.48% of that.
The stock has a current market capitalization of $3.73B and its 3Y-monthly beta is at 0.31. It has posted earnings per share of -$0.99 in the same period. It has Quick Ratio of 10.96 while making debt-to-equity ratio of 0.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CBAY, volatility over the week remained 0.07% while standing at 0.20% over the month.
Analysts are in expectations that Cymabay Therapeutics Inc (CBAY) stock would likely to be making an EPS of -$0.31 in the current quarter, while forecast for next quarter EPS is -$0.34 and it is -$1.15 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.39 which is -$0.26 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.29 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -45.94% while it is estimated to increase by 34.54% in next year.
Coverage by UBS stated Cymabay Therapeutics Inc (CBAY) stock as a Buy in their note to investors on August 14, 2023, suggesting a price target of $18 for the stock. Stock get a Buy rating from BTIG Research on March 09, 2023.
